Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept

doi:10.4254/wjh.v16.i4.490

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (283)

All Articles published online

The chart showing PDF series, HTML series.

Item

Count

PDF

HTML

244

Sum=251

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=19

Apr 27, 2024 (publication date) through May 6, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Hepatol. Apr 27, 2024; 16(4): 490-493
Published online Apr 27, 2024. doi: 10.4254/wjh.v16.i4.490

Erdafitinib and checkpoint inhibitors for first-line and second-line immunotherapy of hepatic, gastrointestinal, and urinary bladder carcinomas: Recent concept

Mohamed Wishahi

Mohamed Wishahi, Department of Urology, Theodor Bilharz Research Institute, Cairo 12411, Egypt

Author contributions: Wishahi M wrote the manuscript, and read and approved the final version of the manuscript.

Conflict-of-interest statement: The author declares no conflict of interest of any kind in connection to the content of this work.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Mohamed Wishahi, MD, PhD, Professor, Surgical Oncologist, Department of Urology, Theodor Bilharz Research Institute, Embaba, Giza, Cairo 12411, Egypt. moh.weshahy@gmail.com

Received: November 21, 2023
Peer-review started: November 21, 2023
First decision: January 24, 2024
Revised: February 8, 2024
Accepted: March 26, 2024
Article in press: March 26, 2024
Published online: April 27, 2024

Core Tip

Core Tip: The promising results of first-line treatment of advanced and metastatic urothelial carcinoma with programmed cell death protein 1 blockades with single or combined agents, indicate a new concept in the treatment of advanced, metastatic, and recurrent hepatic and gastrointestinal carcinomas. Cancer immunotherapy as a first-line treatment will improve overall survival and quality of life. At present, cancer immunotherapy as first-line treatment in invasive carcinomas or as second-line treatment in recurrent or metastatic carcinoma following the standard chemotherapy is applied on a case-by-case basis.